SYRE•benzinga•
Spyre Therapeutics Announces First Participant Dosed In Its Phase 1 Trial Of SPY003, Its Novel Half-life Extended IL-23 Antibody
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 27, 2025 by benzinga